<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   What's new in sleep medicine
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       What's new in sleep medicine
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        What's new in sleep medicine
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 22, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p>
         The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.
        </p>
        <p class="headingAnchor" id="H304_143610">
         <span class="h1">
          SLEEP-RELATED BREATHING DISORDERS
         </span>
        </p>
        <p class="headingAnchor" id="H143610">
         <span class="h2">
          Management of residual excessive sleepiness in obstructive sleep apnea (January 2024)
         </span>
        </p>
        <p>
         The first expert consensus statement on the management of residual excessive sleepiness (RES) in patients with obstructive sleep apnea (OSA) was recently published [
         <a href="#rid1">
          1
         </a>
         ]. Key points include the assessment of RES at regular intervals throughout the patient's life, use of the Epworth Sleepiness Scale and detailed clinical sleep (including sleep deprivation and inadequate sleep), neurologic evaluation to comprehensively investigate non-OSA RES etiologies, and evaluation of adequate adherence to and optimal application of positive airway therapy before embarking on wakefulness-promoting agents. We agree with these recommendations. (See
         <a class="medical medical_review" href="/z/d/html/7687.html" rel="external">
          "Evaluation and management of residual excessive sleepiness in adults with obstructive sleep apnea", section on 'Evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H305_142939">
         <span class="h1">
          INSOMNIA
         </span>
        </p>
        <p class="headingAnchor" id="H143932">
         <span class="h2">
          Risk of fractures with benzodiazepine receptor agonists (January 2024)
         </span>
        </p>
        <p>
         Benzodiazepine receptor agonists (BZRAs), including benzodiazepines and nonbenzodiazepine BZRAs such as
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         , can cause excess drowsiness and imbalance leading to falls and fractures. In a recent meta-analysis of 20 observational studies in over six million individuals, BZRAs were associated with increased risk of osteoporotic fractures across a range of drug classes and fracture types, with odds ratios ranging from 1.2 to 1.4 [
         <a href="#rid2">
          2
         </a>
         ]. Most but not all studies included adults 50 years of age or older. These data reinforce the need for caution in prescribing BZRAs for insomnia and other indications, particularly in older adults. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Special populations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H142939">
         <span class="h2">
          Nurse-delivered brief behavioral treatment for insomnia (October 2023)
         </span>
        </p>
        <p>
         A growing body of evidence supports the use of brief, behaviorally-focused treatments for insomnia, which involve fewer sessions than traditional cognitive behavioral therapy and can be delivered by clinicians with varied levels of expertise. In an open-label randomized trial in England involving nearly 650 adults with insomnia disorder recruited from 35 general practices, four sessions of nurse-delivered sleep restriction therapy (
         <a class="graphic graphic_table graphicRef122801" href="/z/d/graphic/122801.html" rel="external">
          table 1
         </a>
         ) improved patient-reported insomnia severity scores and six-month response rates compared with a sleep hygiene booklet alone (
         <a class="graphic graphic_table graphicRef122804" href="/z/d/graphic/122804.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Training nurses or advanced practice providers to deliver brief behavioral treatments may be a feasible and cost-effective way to improve outcomes for insomnia. (See
         <a class="medical medical_review" href="/z/d/html/97869.html" rel="external">
          "Cognitive behavioral therapy for insomnia in adults", section on 'Brief behavioral treatment approaches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H306_142616">
         <span class="h1">
          CENTRAL DISORDERS OF HYPERSOMNOLENCE
         </span>
        </p>
        <p class="headingAnchor" id="H142616">
         <span class="h2">
          Liver injury halts trials of novel oral orexin agonist (September 2023)
         </span>
        </p>
        <p>
         Novel therapies are under investigation for narcolepsy with cataplexy, which is associated with loss of orexin-producing neurons in the hypothalamus. Recently, two phase II trials of an oral orexin 2 receptor-selective agonist, TAK-994, showed improvements in sleepiness and cataplexy in patients with narcolepsy but were halted early due to clinically important elevations in liver enzymes and drug-induced liver injury in several patients [
         <a href="#rid4">
          4
         </a>
         ]. Other orexin agonists are in development. (See
         <a class="medical medical_review" href="/z/d/html/131001.html" rel="external">
          "Management and prognosis of narcolepsy in children", section on 'Emerging therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H308_143195">
         <span class="h1">
          PARASOMNIAS AND SLEEP-RELATED MOVEMENT DISORDERS
         </span>
        </p>
        <p class="headingAnchor" id="H143195">
         <span class="h2">
          Neurostimulation device for restless legs syndrome (November 2023)
         </span>
        </p>
        <p>
         Noninvasive neuromodulation techniques are of interest for treatment of restless legs syndrome (RLS). One new device, tonic motor activation (TOMAC), delivers peroneal nerve stimulation via bilateral therapy units worn externally just below the knee, over the head of the fibula. In a randomized sham-controlled trial of TOMAC in 133 adults with medication-refractory RLS, TOMAC improved clinician-rated responses and RLS severity scores at 4 weeks [
         <a href="#rid5">
          5
         </a>
         ], and the device was well tolerated for up to 24 weeks [
         <a href="#rid6">
          6
         </a>
         ]. TOMAC received marketing approval in the United States in 2023 [
         <a href="#rid7">
          7
         </a>
         ], and availability is anticipated in 2024. (See
         <a class="medical medical_review" href="/z/d/html/88241.html" rel="external">
          "Management of restless legs syndrome and periodic limb movement disorder in adults", section on 'Neurostimulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H310_142612">
         <span class="h1">
          GENERAL SLEEP MEDICINE
         </span>
        </p>
        <p class="headingAnchor" id="H143862">
         <span class="h2">
          Effect of short-term sleep restriction on insulin sensitivity in females (January 2024)
         </span>
        </p>
        <p>
         Short sleep duration has been associated with risk of type 2 diabetes, but whether this reflects a causal relationship is uncertain. In a crossover study in 38 females aged 20 to 75 years with baseline sleep duration of seven to nine hours nightly, participants underwent sequential, six-week phases of sleep maintenance (usual sleep time maintained) and sleep restriction (sleep time reduced by 1.5 hours nightly) [
         <a href="#rid8">
          8
         </a>
         ]. Sleep restriction led to increases in fasting insulin concentration and homeostasis model assessment of insulin resistance (HOMA-IR), indicating diminished insulin sensitivity. These changes were independent of changes in adiposity and were more pronounced in postmenopausal compared with premenopausal participants. Further studies are needed to verify the findings in a larger cohort of patients, including males, and to determine whether prolonged sleep restriction causes progressive worsening of glucose homeostasis. (See
         <a class="medical medical_review" href="/z/d/html/1771.html" rel="external">
          "Type 2 diabetes mellitus: Prevalence and risk factors", section on 'Sleep duration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H142612">
         <span class="h2">
          Lack of evidence that blue light-filtering lenses improve sleep (September 2023)
         </span>
        </p>
        <p>
         Blue light-filtering glasses are marketed widely to reduce adverse effects of light-emitting screens on sleep, but supporting evidence is lacking. A recent systematic review identified six small randomized trials examining sleep outcomes with use of blue light-filtering lenses [
         <a href="#rid9">
          9
         </a>
         ]. Trial results were inconsistent, and meta-analysis could not be performed due to high heterogeneity and lack of quantitative outcome data. We counsel patients to avoid use of electronics at least 30 minutes before usual bedtime and in the middle of the night if nocturnal awakenings occur (
         <a class="graphic graphic_table graphicRef122804" href="/z/d/graphic/122804.html" rel="external">
          table 2
         </a>
         ). Based on available evidence, we advise that blue light-filtering glasses are not a substitute for avoidance of screens. (See
         <a class="medical medical_review" href="/z/d/html/97866.html" rel="external">
          "Insufficient sleep: Evaluation and management", section on 'Counseling on lifestyle changes'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Steier JS, Bogan RK, Cano-Pumarega IM, et al. Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea - A Delphi consensus study. Sleep Med 2023; 112:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu C, Leung JCN, Shi J, et al. Sedative-hypnotics and osteoporotic fractures: A systematic review of observational studies with over six million individuals. Sleep Med Rev 2024; 73:101866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyle SD, Siriwardena AN, Espie CA, et al. Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial. Lancet 2023; 402:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauvilliers Y, Mignot E, Del Río Villegas R, et al. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. N Engl J Med 2023; 389:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogan RK, Roy A, Kram J, et al. Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial. Sleep 2023; 46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy A, Ojile J, Kram J, et al. Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study. Sleep 2023; 46.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration (FDA) device classification under section 513(f)(2)(de novo) available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN220059 (Accessed on October 26, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuraikat FM, Laferrère B, Cheng B, et al. Chronic Insufficient Sleep in Women Impairs Insulin Sensitivity Independent of Adiposity Changes: Results of a Randomized Trial. Diabetes Care 2024; 47:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Keller PR, Busija L, et al. Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults. Cochrane Database Syst Rev 2023; 8:CD013244.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 107235 Version 12473.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37839271" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea - A Delphi consensus study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37926010" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sedative-hypnotics and osteoporotic fractures: A systematic review of observational studies with over six million individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37573859" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37494485" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37458698" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37439365" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37439365" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Long-term efficacy and safety of tonic motor activation for treatment of medication-refractory restless legs syndrome: A 24-Week Open-Label Extension Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37955852" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chronic Insufficient Sleep in Women Impairs Insulin Sensitivity Independent of Adiposity Changes: Results of a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37593770" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
